What sector does Corona Remedies Limited belong to?

Corona Remedies Limited operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of CORONA?

As of the latest available quote, CORONA traded at ₹2,228.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of CORONA?

Corona Remedies Limited has a price-to-earnings (P/E) ratio of about 68.24. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of CORONA?

The market capitalisation of Corona Remedies Limited is approximately ₹13,676 Cr.

Is Corona Remedies Limited profitable?

For its latest reported financial year, Corona Remedies Limited recorded a net profit margin of about 13.19%.

Does CORONA pay a dividend?

Corona Remedies Limited currently has a dividend yield of about 0.45%.

What is the return on equity (ROE) of CORONA?

Corona Remedies Limited has a return on equity (ROE) of about 29.50%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of CORONA?

Over the past 52 weeks, CORONA has traded between a low of ₹1,336.60 and a high of ₹2,270.10.

Corona Remedies Limited

CORONA NSE Healthcare Pharmaceuticals

Microcap 250

₹2,228.00

+1.24%

Delayed · cached 15 min

Fair value analysis

CORONA

Corona Remedies Limited

₹2,200.80

Close used for this calculation

₹756.75Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

56/100

Profitability21/25

Returns10/25

Balance Sheet19/25

Efficiency6/25

Growth12/25

Good

Quality radar

Consensus fair value

₹756.75

Above FV

▼ -65.6% against the close used

Model range ₹178.87 – ₹1,080.64

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹178.87Fair value₹756.75Bull₹1,080.64

FairClose

52-week traded range

52W low ₹1,347.7052W high ₹2,200.80

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Corona Remedies Limited closed at ₹2,200.80, 190.8% above the consensus fair value of ₹756.75 drawn from 8 valuation models.

Financial DNA score 56/100 — Good. P/E of 64.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹178.87

-91.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹306.27

-86.1%

√(22.5 × EPS × BVPS)

EPS=30.27, BVPS=137.72 · outside Graham range (P/E 64.4, P/B 16) — asset-light, treat as a rough floor

P/E Fair Value

₹1,080.64

-50.9%

EPS × 35.7x (sector P/E)

EPS=30.27, Sector P/E=35.7x

Peter Lynch (PEG)

₹756.75

-65.6%

EPS × Growth% (PEG = 1 is fair)

EPS=30.27, g=25%

EV/EBITDA

₹935.13

-57.5%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=3.32B

Book Value (P/B)

₹809.12

-63.2%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=137.72, ROE=29.5%, g=6%, r=10%

Reverse DCF

₹2,200.80

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 24.7% | Historical: 25%

Margin of Safety

₹391.45

-82.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=521.93, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer